World Library  
Flag as Inappropriate
Email this Article


ViroPharma Incorporated
Public NASDAQ Biotechnology Index
Traded as NASDAQ: VPHM
Industry Healthcare, Biotechnology, Pharmaceutical company
Founded Exton, Pennsylvania, U.S. (1994)
Headquarters Exton, Pennsylvania, U.S.
Key people
Claude H. Nash (founding CEO)
Vincent Milano, Chairman and CEO
Products Vancocin
Revenue 132,417,000 USD (2005)
88,145,000 USD (2005)
113,705,000 USD (2005)
Number of employees

ViroPharma Incorporated was a pharmaceutical company that developed and sold drugs that addressed serious diseases treated by physician specialists and in hospital settings. The company focused on product development activities on viruses and human disease, including those caused by cytomegalovirus (CMV) and hepatitis C virus (HCV) infections. It was purchased by Shire in 2013, with Shire paying around $4.2 billion for the company in a deal that was finalized in January 2014.[2] ViroPharma was a member of the NASDAQ Biotechnology Index and the S&P 600.

The company had strategic relationships with GlaxoSmithKline, Schering-Plough, and Sanofi-Aventis. ViroPharma acquired Lev Pharmaceuticals in a merger in 2008.[3][4]


  • History 1
  • Board of directors 2
  • Management team 3
  • Products 4
    • Marketed products 4.1
    • Pipeline 4.2
    • Failed products 4.3
  • References 5
    • Further references 5.1
  • External links 6


ViroPharma Incorporated was founded in 1994 by Claude H. Nash (Chief Executive Officer), Mark A. McKinlay (Vice President, Research & Development), Marc S. Collett (Vice President, Discovery Research), Johanna A. Griffin (Vice President, Business Development), and Guy D. Diana (Vice President, Chemistry Research.) None of the founders are still with the company.

In November 2014, Shire plc acquired ViroPharma for$4.2 billion.[5]

Board of directors

Management team


Marketed products

Vancocin Pulvules HCl: licensed from Eli Lilly in 2004.[6] Oral Vancocin is an antibiotic for treatment of staphylococcal enterocolitis and antibiotic associated pseudomembranous colitis caused by Clostridium difficile.


Maribavir is an oral antiviral drug candidate licensed from GlaxoSmithKline in 2003 for the prevention and treatment of human cytomegalovirus disease in hematopoietic stem cell/bone marrow transplant patients. In February 2006, ViroPharma announced that the United States Food and Drug Administration (FDA) had granted the company fast track status for maribavir.

In March 2006, the company announced that a Phase II study with maribavir demonstrated that prophylaxis with maribavir displays strong antiviral activity, as measured by statistically significant reduction in the rate of reactivation of CMV in recipients of hematopoietic stem cell/bone marrow transplants. In an intent-to-treat analysis of the first 100 days after the transplant, the number of subjects who required pre-emptive anti-CMV therapy was statistically significantly reduced (p-value = 0.051 to 0.001) in each of the maribavir groups compared to the placebo group (57% for placebo vs. 15%, 30%, and 15% for maribavir 100 mg twice daily, 400 mg daily, and 400 mg twice daily, respectively).

ViroPharma conducted a Phase III clinical study to evaluate the prophylactic use for the prevention of cytomegalovirus disease in recipients of allogeneic stem cell transplant patients. In February 2009, ViroPharma announced that the Phase III study failed to achieve its goal, showing no significant difference between maribavir and a placebo in reducing the rate of CMV disease.[7]

Failed products

Oral pleconaril was ViroPharma's first compound, licensed from Sanofi in 1995. Pleconaril is active against viruses in the picornavirus family. ViroPharma's first indication was for enteroviral meningitis, but that indication was abandoned when the clinical trials did not demonstrate efficacy.

In 2001, ViroPharma submitted a New Drug Application of pleconaril to the FDA for the common cold.[8] On 2002-03-19, the FDA Antiviral Advisory Committee recommended that the company had failed to show adequate safety, and the FDA subsequently issued a not-approvable letter.[9]

In November 2003, ViroPharma licensed pleconaril to Schering-Plough, who are developing an intranasal formulation for the common cold and asthma exacerbations. (Schering-Plough Development Pipeline). In August 2006, Schering-Plough started a Phase II clinical trial.


  1. ^
  2. ^ Shire Buys ViroPharma for $4.2 Billion to Add Orphan Drug, 11-11-2013
  3. ^ Staff (2008-07-15). "ViroPharma to Purchase Lev for $442.9M". Genetic Engineering & Biotechnology News. GEN News Highlights (Mary Ann Liebert).  
  4. ^ "Lev Pharmaceuticals Investor Relations". Lev Pharmaceuticals. Retrieved 2009-04-08. 
  5. ^ Kitamura, Makiko (11 November 2013). "Shire Buys ViroPharma for $4.2 Billion to Add Orphan Drug". Bloomberg. 
  6. ^ Pollack, Andrew (2005-11-09). "Crucial Antibiotic Rescues Biotech Maker's Finances".  
  7. ^ ViroPharma:Maribavir Phase III Study Missed Goal;Shares Plunge, CNN Money, February 09, 2009
  8. ^ Freundlich, Naomi (2002-02-03). "On the Trail of a Cure For the Common Cold".  
  9. ^ Pollack, Andrew (2002-03-20). "F.D.A. Panel Opposes Drug Meant to Treat Cause of Colds".  

Further references

  • The Long Road Ahead for ViroPharma Motley Fool 29 September 2006
  • McDonald LC, Killgore GE, Thompson A, et al. 2005 Emergence of an epidemic, toxin gene variant strain of Clostridium difficile responsible for outbreaks in the United States between 2000 and 2004" N Engl J Med 353:2433-2441 [3]
  • U.S. Centers for Disease Control and Prevention Report on Severe Clostridium difficile—Associated Disease in Populations Previously at Low Risk --- Four States, 2005 [4]
  • Lu H, Thomas S. 2004. Maribavir (ViroPharma). Curr Opin Investig Drugs 5:898-906
  • Fleischer R, Laessig K (2003). "Safety and efficacy evaluation of pleconaril for treatment of the common cold". Clin. Infect. Dis. 37 (12): 1722.  
  • Hayden FG, Herrington DT, Coats TL, Kim K, Cooper EC, Villano SA, Liu S, Hudson S, Pevear DC, Collett M, McKinlay M (2003). "Efficacy and safety of oral pleconaril for treatment of colds due to picornaviruses in adults: results of 2 double-blind, randomized, placebo-controlled trials". Clin. Infect. Dis. 36 (12): 1523–32.  

External links

This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.

Copyright © World Library Foundation. All rights reserved. eBooks from World eBook Library are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.